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1. Introduction
Autoimmune  diseases  result  from  specific  immune  response  to  structures  of  the  self.
Such  a  response,  resulting  from  activation  of  self-specific  lymphocytes,  is  an  inevitable
side effect of the work of the immune system. However, mechanisms of central and pe‐
ripheral  tolerance normally prevent  damage to tissues of  the organism, blocking activa‐
tion and proliferation of autoreactive lymphoid cells. Thus, it would be more accurate to
say that autoimmune diseases result from breakdown of tolerance mechanisms that leads
to chronic self-sustained response against the structures of the self. Autoimmune diseases
should be  discriminated from autoimmune reactions.  The latter  are  associated with  im‐
mune response  against  infectious  pathogens  and stop  immediately  after  the  pathogenic
agent is eliminated. Autoimmune diseases are also quite frequently associated with cross-
reactive immune response to exogenous pathogens. In fact, such a link is implicated into
pathogenesis of most of those diseases. However, autoimmune diseases continue to prog‐
ress even if the pathogen is cleared.
The key feature that distinguishes “normal” autoimmunity from pathological conditions is
breakdown of tolerance that takes place in the latter case. This difference is illustrated by
comparing characteristics of autoantibodies present in normal organism with characteristics
of autoantibodies in patients with autoimmune diseases. Apart from higher titers in the pa‐
tients with autoimmune diseases, antibodies in those patients also show higher avidity to
target antigen and mono\oligoclonal structure, as opposed to polyclonal structure in nor‐
mal samples. In normal organism, detected autoantibodies typically belong to IgM isotype,
© 2013 Krynskiy et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
while in pathology they usually belong to IgG isotype. This has an important implication, as
production of IgG antibodies can not be mediated by B-lymphocytes alone. It practically al‐
ways requires involvement of antigen-specific CD4+ T-cells, which illustrates that pathogen‐
esis of autoimmune diseases is a complex multistep process, requiring breakdown of
tolerance on several levels.
Normal samples Samples from patients with autoimmune conditions
Isotype IgM IgG
Affinity Low High
Clonal structure Polyclonal Usually oligoclonal or monoclona
Titer Low High
Table 1. Autoantibody characteristics in normal individuals compared to those n individuals having a tissue-specific
autoimmune disease.
Etiology of autoimmune diseases remains obscure, along with factors that serve as triggers
for the disease. Nowadays it seems obvious that neither genetic predisposition nor environ‐
mental factors alone are sufficient for causing the disease. The common concept is that auto‐
immune diseases arise from complex interaction between genetic factors and environment.
The conception of post-infectious autoimmune syndrome (PIFAS) defines infection as an im‐
portant component of pathogenesis (Foy et al., 1996). According to this conception, autoim‐
mune diseases develop in genetically predisposed organisms as a result of specific infection
causing cross-reactive immune response affecting own cells and tissues of the organism.
Later this response becomes self-sustained and can continue even in the absence of infec‐
tious agent that caused it in the first place. In accordance with this conception, evidence aris‐
es that in most cases of autoimmune conditions, the primary event of pathogenesis is
infection. Arguments that support role of infection in specific autoimmune diseases can be
divided into several categories: clinical (clinical findings, as in the case of acute rheumatic
fever following streptococcal infections), epidemiological (obtained in epidemiological stud‐
ies that fit criteria of evidence-based medicine), laboratory (based on laboratory diagnostics
of infection in the past, i.e. by accessing antibody levels in biological fluids or obtaining
DNA of the pathogen from tissues affected by immune response).
These criteria are applied to show correlation between presence of an infectious agent in the
organism and an autoimmune condition. Once such correlation has been found, the next
step is studying mechanisms that mediate induction of disease. In relation to pathogens in
question, such mechanisms can be divided into specific (those that include stimulation of
antigen-specific clones of lymphocytes) and non-specific (based on causing appropriate in‐
flammatory environment for disease induction) (Goodnow et al., 2007). Deeper insight into
the problem shows that several of these mechanisms have to be active to initiate an autoim‐
mune response, and that both specific and non-specific mechanisms typically contribute to
pathogenesis equally.
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2. Mechanisms of tolerance: An overview
A number of mechanisms is at work to prevent negative effects associated with autoimmune
reactions. The conception of tolerance has been introduced to explain those mechanisms.
Tolerance is lack of reactivity of the immune system to antigens of the body. Tolerance is an
active process that can be induced through central and peripheral mechanisms. Central tol‐
erance refers to processes taking place during lymphocyte differentiation in central lym‐
phoid organs, before activation (in the process of antigen-independent differentiation of
lymphocytes). A classic example of central tolerance is negative selection of T-lymphocytes
that takes place during their maturing in the thymus. Selection of lymphocytes in the thy‐
mus includes two stages. On the first stage cells that have low ability to react with own mol‐
ecules of major histocompartibility complex (MHC) undergo apoptosis. Ability to react with
own MHC is necessary for proper T-cell function, since T-cells respond only to antigen frag‐
ments presented by antigen-presenting cells (APCs) in complex with MHC molecules (B-
cells, on the other hand, respond to full molecules of antigens and don’t require interaction
with MHC). On the second stage cells that undergo apoptosis are those that strongly react
with fragments of own antigens of the body presented by MHC (the so-called negative se‐
lection). Therefore, cells that survive do have ability to react with own MHC, but not too
strong an ability. Those cells also have low potential to respond to own antigen fragments.
Such a complex process of selection is necessary, because T-cells have a central role in specif‐
ic immune responses, and consequences of a tolerance breakdown at T-cell level would be
quite grave. However, it should be noted that possibility of response to own pathogens is an
inevitable side effect of the mechanisms T-cells utilize in their receptor mechanisms (require‐
ment of interaction with own MHC molecules). In B-cells the mechanisms of selection don’t
differ principally from those in T-cells, however they are much less strict.
The  described  mechanisms  aren’t  sufficient  to  fully  prevent  appearance  of  autoreactive
clones in the blood. However,  activation of T-cells requires several conditions to be met
(apart from interaction of the antigen-specific receptor with its  target).  Appropriate con‐
tact between T-cell and APC is called immune synapse. A key condition for a successful
activation  is  interaction  of  CD28  molecule  of  the  T-cell  with  costimulatory  molecules
B1/B7 of the APC. Without such interaction, activation of TCR causes anergy or apopto‐
sis of the lymphocyte. This interaction is unlikely in the absence of appropriate costimu‐
lation,  which  is  induced  by  presence  of  non-specific  molecular  signals  of  “presence  of
danger” (DAMPs – Danger associated molecular patterns) or “presence of an infectious
agent” (PAMPs – Pathogen associated molecular patterns). The latter include fragments
of bacterial cellular wall, exogenous DNA, flagellin, etc. Those factors cause activation of
APCs, increasing expression of MHC-antigen complexes and costimulatory molecules. In
the  event  of  interaction  of  an  autoreactive  T-lymphocyte  with  its  target,  the  described
costimulation is not expected to be active. That means that APCs would not be activated,
and won’t express necessary amounts of B1/B7. Expression of MHC molecules would al‐
so  remain  low.  This  mechanism  of  control  ensures  that  T-cell  activation  seldom  takes
place without activation of innate immunity. As a result, autoreactive T-lymphocytes that
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interact with self-antigens more often than not undergo apoptosis or become anergic as a
result of TCR stimulation without appropriate costimulation.
Activation of B-cells doesn’t require antigen presentation in association with MHC. These
cells have the ability to recognize antigens directly through BCR. However, as well as in
the case of T-cells, stimulation of BCR has to be coupled with costimulatory mechanisms,
or the cell would most likely undergo apoptosis. Signals inducing B-cells proliferation in‐
clude interaction with PAMPs.  Those are mediated by toll-like receptors (TLRs) that  in‐
teract with PAMPs, and complement C3 receptor (CD21), that binds to C3 component of
the  complement.  C3 binds  to  specific  components  of  the  mictobial  cell  wall  (alternative
complement  activation),  or  to  pathogens  opsonised with  antibodies  (classic  complement
activation).  Those  mechanisms  direct  immune  response  towards  reaction  to  microbial
pathogens bearing signs of “danger”.
Before the start of B-cell antigen dependent differentiation and antibody production, B-cells
have to pass another checkpoint (Goodnow et al., 2007). That is interaction with T-cells spe‐
cific for the same antigen, through CD40/CD40L system (Foy et al., 1996). Therefore, interac‐
tion of two antigen-specific cells, both of which have undergone multiple points of selection,
is required before B-cell mediated immune response with highly-affined antibody produc‐
tion and memory cells formation can take place. Functional activity of the immune system is
preciously regulated to minimize chances of autoimmune reaction.
Another mechanism controlling the activity of immune response is activity of regulatory T-
cells (Treg). Natural Tregs have the phenotype of CD4+CD25low, and express a specific
transcription factor – Foxp3. Foxp3 mediates suppressor function by inducing factors such
as TGFbeta, GITR, IL-10. Upon activating, Treg cells specifically inhibit immune response.
An important feature of their cells is that their TCRs show significantly higher affinity to
own antigens than those in other T-cells. It is thought that cells with affinity to self-antigens
higher than in most T-cells but lower than is required for negative selection may differenti‐
ate into Treg (Wan et al., 2007). There are also other types of regulatory lymphoid cells with
suppressor function, such as induced Treg that form in vivo in conditions of activated
CD4+-cells stimulation with IL-10, and B-regulatory cells.
An important function of mechanisms of tolerance is degenerative feedback for countering
uncontrolled immune cells activation. Continuous stimulation of TCR causes negative regu‐
lation of CD 28 receptor needed for T-cell costimulation through B1 and B7 molecules of the
APCs. Instead, T-cells start producing CTLA (CD 28), a molecule that is an antagonist for B1
and B7. This cuts costimulation of T-cells and causes induction of anergy.
3. Role of infection: The conception of PIFAS
Seeing that  autoimmune diseases  arise  from lack of  balance  between stimulation of  the
immune system and activity of suppressor mechanisms, infection, especially chronic, pro‐
poses to be an important factor in the induction of autoimmune process.  Even by itself,
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chronic  antigen  stimulation  accompanied  by  lymphocyte  proliferation  and  activation  of
effector mechanisms significantly magnifies the chance of breakdown in tolerance mecha‐
nisms.  A parallel  can be drawn between autoimmune conditions and tumors of  the im‐
mune  system.  The  latter,  rising  from  uncontrolled  proliferation  of  lymphocytes,  have
been firmly associated with excessive chronic antigen stimulation (chronic infection with
HIV, Hepatitis C, Epstein-Barr virus).
The conception of PIFAS distinguishes the following 5 steps in the pathogenesis of autoim‐
mune diseases (Cherepachina et al., 2009):
1. Genetic predisposition.
2. Infectious process causing cross-reactive activation of the immune system.
3. Latent stage of the autoimmune disease characterized by production of autoantibodies
and antigen-specific clones of lymphocytes. It is accompanied by morphological signs
of immune inflammation (i.e., latent autoimmune insulitis preceding manifestation of
autoimmune diabetes mellitus) and can be detected by accessing the proteome of the
patient. Markers that can be detected in the proteome are divided into markers of im‐
mune inflammation and markers of tissue degeneration.
4. Latent stage of the disease accompanied by impairment of functional activity of the af‐
fected tissues which cab be detected by functional diagnostics or by accessing the me‐
tabolome of the patient.
5. Manifest stage of the disease.
4. Pathogenetic mechanisms of autoimmune diseases
Now we shall give a more detailed description of mechanisms that have a role in the patho‐
genesis of autoimmune diseases.
4.1. Molecular mimicry
The conception of molecular mimicry is one of the most common concepts in immunology.
It is also the simplest hypothesis that can be applied to explain the etiology of autoimmune
diseases. The conception is built on laboratory findings that show homology between amino
acid sequences of infectious agents and those of proteins of the body. Activation of T-cells
with TCR specific for the pathogen causes cross-reactive reaction to own antigens of the or‐
ganism, and as a result, impairment of functions of target organs. For the pathogen this
serves as a mechanism of evading the immune response, since self-reactive clones of lym‐
phocytes are typically less active due to mechanisms of negative selection, and are also
prone to suppression by mechanisms of peripheral tolerance. This interferes with elimina‐
tion of the pathogen (Sherbet, 2009). And long-term persistence of the pathogen contributes
even further to the ongoing autoimmune reaction. Such a reaction may or may not come to
an end after and if the infectious agent is finally eliminated. In the latter case, the process
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becomes self-supporting, recruiting other mechanisms of disease progression. If secondary
production of self-reactive T-lymphocyte clones takes place, as opposed to just antibody
production, this usually marks the onset of autoimmune disease. An important factor here is
the phenomenon of epitope spreading, which is caused by changes in conformation of anti‐
gens that are subject to immune response (see later).
4.2. Superantigens
As opposed to specific monoclonal stimulation of immune system caused by antigens, stim‐
ulation by superantigens causes polyclonal activation of cells of the immune system. Mecha‐
nisms of superantigen-mediated activation primarily affect T-cells activation. Stimulation by
antigens causes activation of T-cells as a result of presentation of processed antigen by MHC
molecules of the APCs. TCR binds to the peptide presented by MHC. Superantigens react
directly with MHC molecules, binding to beta-unit of the molecule (Conti-Fine et al., 1997).
They cause non-specific polyclonal activation of T-cells, reacting with all cells that can bind
to appropriate MHC-molecule (all cells that are restricted to the haplotype of that MHC
molecule). Participation of superantigens in the pathogenesis of autoimmune diseases seems
to be indirect. One of the aspects is their contribution to inflammatory response and antigen
presentation (mostly due to stimulation of macrophages by activated CD4+ Th1-cells).
Pathogenic agents producing superantigens can also contribute to pathogenesis of autoim‐
mune diseases by increasing the possibility of activation of autoreactive T-cells as a compo‐
nent of polyclonal activation.
4.3. Altered presentation of own antigens
The next component of pathogenesis is abnormal presentation of self-antigens caused by in‐
flammatory response to infectious pathogens. This can refer to increased expression of HLA-
molecules (Conti-Fine et al, 1997), aberrant expression of HLA molecules, presentation of
antigens that are normally invisible for the immune system. These phenomena are frequent‐
ly seen as a component of normal immune reactions (hence another important implication of
infectious agents in the pathogenesis) or autoimmune inflammatory reactions.
It is a well known fact that stimulation with inflammatory cytokines causes an increase in
expression of MHC molecules. This refers both to professional APCs (macrophages, B-lym‐
phocytes, dendritic cells) and most other cell lines (in the latter case, expression of HLA I is
increased, making the cells vulnerable to autoreactive CD8+ cytotoxic lymphocytes). Inflam‐
matory signaling also stimulates aberrant expression of MHC, causing expression of HLA II
by endothelial cells, fibroblasts and other cell lines that normally only express HLA I and
don’t function as antigen-presenting cells. Such aberrant expression of HLA molecules may
lead to presentation of antigen determinants of the self that were previously unknown to the
immune system.
Presentation of normally invisible antigens may occur as a result of breakdown of specific
blood-brain barriers of “immunologically privileged” organs. This mechanism plays an im‐
portant role in the pathogenesis of autoimmune uveitis, multiple sclerosis, etc.
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4.4. Presentation of altered self-antigens. Epitope spreading
Disclosure of cryptic antigenic epitopes is an important mechanism in the progression of au‐
toimmune diseases (Lehmann et al., 1997). Normal conformation of the body’s proteins
makes some epitopes invisible to antigen-recognizing receptors of the immune system. Con‐
formation of peptides prevents those epitopes from being recognized by lymphoid cells.
However, that also means that lymphocyte clones specific to those antigens do not get elimi‐
nated effectively during antigen-independent differentiation. Disclosure of those epitopes
which may take place as a result of changes in protein conformation that result from im‐
mune inflammation may open up these epitopes for effective immune response. Those new
targets for autoimmune reaction may have significantly higher affinity to antigen-recogniz‐
ing receptors in comparison to the original ones. Clinically such an event is frequently asso‐
ciated with the disease taking rapidly progressive course, for example, with multiple
sclerosis reaching secondary progressive type. The described phenomenon is known as epit‐
ope spreading – a process that is tightly associated with autoimmune diseases progression.
5. Conception of PIFAS as applied to explaining pathogenesis of
autoimmune insulin-dependent diabetes mellitus
5.1. Introduction
Insulin-dependent diabetes mellitus (IDDM) is a chronic autoimmune disorder that results
from autoimmune destruction of insulin-producing pancreatic beta cells. In IDDM, the auto‐
immune process is steadily progressive, inevitably leading to total destruction of Langer‐
hans islet beta-cells and ceasing of production of insulin. Clinical manifestation of the
disease, presented by symptoms of insulin deficiency, takes place quite late into the autoim‐
mune inflammatory process, when about 90% of islet cells have been destroyed (Epstein,
1994). Such a gap between the status of the autoimmune process and clinical symptoms
makes immunosuppressive therapy ineffective in most patients: although application of
such therapy can low the intensity of immune inflammation or in some cases cause a relapse
of the immune inflammation, patient almost always becomes insulin-dependant anyway.
This is largely due to lack of functional reserves in the population of beta-cells at the time of
the diagnosis. Early detection of the autoimmune process in IDDM and identification of risk
factors for the disease would greatly broaden the grounds for pathogenetic therapy, but this
problem has yet to be effectively solved.
Pathogenesis of IDDM includes following stages.
1. Genetic predisposition,
2. Primary immune response aimed at the mimicking infectious pathogen.
3. Latent autoimmune insulitis.
4. Asymptomatic impairment of beta-cell function (impairment of oral glucose tolerance).
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5. Clinical manifestation of the disease.
Diagnostic markers vary for those stages: in the first stage, only markers of genetic predis‐
position can be detected (and used to calculate the risk of disease), while in the third stage it
is possible to detect markers of autoimmune inflammation. In the manifesting stages of the
full-term clinical illness canonical (routine) clinical diagnostic protocols would become pos‐
sible and fruitful. It is evident that the key stage of pathogenesis in which the autoimmune
process becomes irreversible and acquires self-progressive course is the third stage. An im‐
portant task is diagnosing the disease at this stage, when there is room for pathogenetic
therapy aimed at quenching immune inflammation.
5.2. Role of genetic factors in pathogenesis of IDDM
Important peculiarity of T1D pathogenesis is genetic predisposition that conditions the de‐
velopment of the disease. MHC (major histocompartibility complex) often elicits autoim‐
mune responses by predetermining the inadequate behavior of immunocompetent cells.
MHC represents a large family of genes encoding molecules of three major HLA (human
leukocyte antigen) classes.
HLA class I
The HLA class I compartment contains both diabetoprotective genotypes and highly asso‐
ciative genes. HLA class I initiate and potentiate autoimmune destruction of beta cells. The
diabetogenic alleles of MHC class I genes display age-related features. For example, HLA-
E*0101 is predominant in patients in whom T1D developed during the first 10 years of life,
while HLA-E*0103 is found in children under 10. (Kordonouri et al, 2010)
HLA class II
HLA class II constitute a family of genes which encode glycoproteins with an Ig-like struc‐
ture and are predominantly localized on the APCs (antigen presenting cells) surface. Their
functional role covers the presentation of antigen peptides to CD4 (+) T helper cells type I.
Several autoimmune diseases (including T1D) are supported by promoting effects of HLA
class II Ags. (Murdock et al., 2004).
HLA class III
The contribution of HLA class III to background predisposition of T1D is far fewer (com‐
pared to HLA classes I and II) but there are several HLA class III genes manifesting a diag‐
nostically significant association with T1D. As an overall trend, HLA classes II and III
provoke diabetes at the highest levels of the odds ratio, while the effect of HLA class I on
T1D is much less expressed. (Lipponen et al., 2010).
Non-MHC genes also may play a prominent role in the development of autoimmune diseases.
There is quite a vast repertoire of non-MHC genes with a multitude of SNPs (single nucleo‐
tide polymorphism) that determine the attacks at some structural components of the pan‐
creas or directly at insulin. Under certain conditions, e.g., under negative impacts of
environmental factors these genes are “switched on” giving rise to immune disorders.
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An immense variety of genes responsible for susceptibility to T1D are known, but their
functional capabilities are either obscure or poorly investigated. Some genes whose role in
etiology and pathogenesis of T1D leaves no doubt are described below.
TNFAIP3
Tumor necrosis factor, alpha-induced protein 3 is inhibitor of TNF-induced apoptosis. This
gene realizes miscellaneous functions to provide protection of beta cells from programmed
cell death, inactivation of NF-kappa B signals, prevention of inflammatory lesions of pancre‐
atic cells, deceleration or delayed recruitment of immunocompetent cells into target organs,
and so on. Mutations in this gene represent the most common mechanism of disregulation
and disorganization of immune reactions resulting in autoimmunity. (Petrone et al., 2008)
INS
INS (insulin) gene is a key participant in the synthesis of insulin molecules. Proinsulin mole‐
cules are formed during transcription of INS. Mutations in INS are manifested as insulino‐
pathies, e.g., enhanced production of “odd” insulin with impaired amino acid sequences
and atypical conversion of proinsulin into insulin. The latter abnormality is unrelated to
T1D; however, any change in the amino acid sequence may lead to immune failure and se‐
cretion of autoAbs. (Pociot et al., 2002)
ERBB3
ERBB3 (Erythroblastic Leukemia Viral Oncogene Homolog) modulates the presentation of
Ags and increases the risk of T1D. Mutations in ERBB3 lead to immunoregulatory collapses
coupled with continuous emergence of autoreactive cells.
IL2RA
It regulates immune and inflammatory responses, exerts negative control over cell prolifera‐
tion and favors differentiation of T cells. In addition, IL2RA (interleukin-2 receptor-alpha)
controls apoptosis via a positive feedback mechanism.
Mutation in IL2RA predetermine the susceptibility to T1D by interfering with the transcrip‐
tion and/or splicing of mRNA. In this way, IL2 and IL2RA exert genetic control over protein
expression in different cell subpopulations.
IFIH1
Interferon induced with helicase C domain 1(IFIH1) gene is involved in innate immune de‐
fense against viruses. Upon interaction with intracellular dsRNA(double-stranded RNA)
produced during viral replication, triggers a transduction cascade involving MAVS/IPS1,
which results in the activation of NF-kappa-B, IRF3 and IRF7 and the induction of the ex‐
pression of antiviral cytokines such as IFN-beta and RANTES (CCL5). IFIH1 is directly in‐
volved in the destruction of Langerhans islets due to pooling and mobilization of
autoreactive cells in response to viral invasion. This circumstance aggravates immune disso‐
nance and promotes self-restructuring of targeted organs by provoking persistent deficiency
of the pancreas and accelerating insulin failure.
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CD226 (rs763361) SNPs regulate the activity of certain cells involved in immune mecha‐
nisms mediating beta cell destruction.
5.3. Pathology of IDDM
Morphologic substrate of the disease is autoimmune insulitis, The characteristic feature of
insulitis in patients with IDDM is complete lack of beta cells. Other types of cells in the Lan‐
gerhans islets remain intact. The inflammatory infiltrate consists mostly of CD8+ cells with
some other lymphocytes, macrophages and plasmocytes. Beta-cells of the islets demonstrate
increased expression of HLA I, while the APCs and endothelial cells show increased expres‐
sion of HLA II. This is a characteristic feature of immune inflammation with cell-mediated
immune response.
The key factor in beta-cells destruction is thought to be CD8+-cells-mediated cytotoxycity.
However, CD4+ cells are also crucial for pathogenesis, since blocking their proliferation in
mice hampers the disease progress. This is quite logical, since, CD8+ cells activation requires
participation of CD4+ cells. Furthermore, it seems that apart from cell-mediated cytotoxyci‐
ty, another mechanism playing just as important role in the disease progression is inflamma‐
tory cytokine production by macrophages and CD4+ cells. Cytokines that have been
implicated in the pathogenesis of IDDM are interleukin-1 (IL-1) and interferon-alpha (Fabris
et al., 1998, Waguri et al., 1994). There have been reports of patients developing fulminant
IDDM in the course of interferon-alpha therapy (Fabris et al., 1998). These and other cyto‐
kines contribute to inflammatory response and promote CD8+ cells activity. IL-1 causes in‐
creased NO production in beta cells which leads to excessive synthesis of free radicals. Beta-
cells are quite sensitive to damage caused by free radicals, which makes them especially
vulnerable to inflammatory responses. This data shows that even non-specific inflammation
can cause beta-cell destruction (and become the foundation for specific autoimmune re‐
sponse to emerge). Apart from creating a condition of increased susceptibility to specific im‐
mune reaction against beta-cells, inflammatory status by itself may cause beta-cells
destruction, as well as serve as a mechanism of stimulation of the immune system with al‐
tered antigens of the destroyed cells.
Autoantibodies present in IDDM include:
• GAD(Glutamic acid decarboxylase) 65 and GAD67 autoantibodies to glutamate decarbox‐
ylase (an enzyme that catalyzes the conversion of glutamic acid into γ-aminobutyric acid
and CO2;
• IA-2(insulinoma antigen 2) autoantibodies to membrane-bound proteins IA-2 and IA-2β;
• ICA (islet cell antibody) autoantibodies to a heterogeneous cluster of antigens expressed
in beta cells;
• ZnT8 autoantibodies to a member of the zinc transporter protein family;
• IAA - autoantibodies to insulin.
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Serving as markers of the autoimmune inflammatory process, these antibodies can be
present before clinical onset of the disease, and can be used for detecting IDDM at latent
stages. The ICA autoantibodies, reacting with cytoplasmic antigens of islet cells, are found
in IDDM patients in 0.5 % of normal subjects and in 70-80 % of patients with newly diag‐
nosed IDDM. Those oligoclonal antibodies react with a variety of antigens. One of those is
pancreatic enzyme glutamate decarboxylase. Presence of ICA autoantibodies in healthy sub‐
jects increases the risk for future development of the disease. The risk is lower for the pa‐
tients with ICA autoantibodies that react with glutamate decarboxylase than for those who
have antibodies specific for other targets. The link is age-dependent, which is attributed to
the risk of autoimmune IDDM being higher in younger people. The disease also takes more
rapid course in younger patients, with less time passing between clinical onset and complete
loss of insulin production.
The anti-insulin antibodies are found in about 50% of patients with newly diagnosed IDDM.
Those antibodies may also originate from insulin administration, which is a case in patients
receiving non-human insulin, and interferes with efficiency of treatment. However, in
IDDM anti-insulin antibodies may represent autoimmune reaction to own tissues, before
any insulin administration. They can be used in combination with islet-cell cytoplasmic au‐
toantibodies for prediction of IDDM development. Combined use of both autoantibodies
greatly increases diagnostic value of the test.
In  vitro,  mononuclear  cells  of  patients  with  IDDM proliferate  in  response  to  glutamate
decarboxylase.  This reaction can be detected earlier than diagnostically significant levels
of anti-glutamate decarboxylase Abs. So, in vitro reaction of mononuclear cells with glu‐
tamate  decarboxylase  is  considered  to  be  one  of  the  earliest  markers  of  autoimmunity
against beta-cells.
5.4. Role of infection in the pathogenesis of IDDM
One of the conceptions proposed to explain the pathogenesis of IDDM is the conception of
molecular mimicry. Pathogens having antigen determinants homological to those of beta-
cells include Coxacie virus (common epitopes with glutamate decarboxylase – an enzyme
characteristic for beta-cells), mumps virus and Chlamidia pneumoniae. There are several
mechanisms that allow viral infection to contribute to pathogenesis. In case of rubella virus
and cytomegalovirus, there is evidence of direct induction of autoimmunity. Infection with
those agents is associated with presence of autoantibodies in newly diagnosed patients with
IDDM. Also, cytomegalovirus has been shown to induce production of antibodies to 38 kDa
protein of the islet cells (Yoon et al., 1990). Those antibodies are frequently detected in pa‐
tients with IDDM. However, as of now there is little reliable data on amino acid sequences
homology between proteins of rubella virus and cytomegalovirus and islet cell antigens.
Another way infectious pathogens can contribute to pathogenesis of IDDM is through direct
cytolytic effect on islet cells. An example is Coxsackie B virus, which mediates immune-in‐
dependent cytolysis of beta-cells (Andreoletti et al., 1998). Coxsackie B virus infection has
been shown to be a risk factor for IDDM (Andreoletti et al., 1998), and homology has been
shown between viral protein 2C and islet cell antigen GAD 65 (Huang et al., 2011). Cytolytic
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effect even further amplifies the contribution of this agent to pathogenesis, as antigen re‐
lease from beta-cells and non-specific inflammatory response greatly facilitate the conditions
for autoimmune reaction.
6. Conception of PIFAS as applicated to explaining pathogenesis of
multiple sclerosis
6.1. Introduction
Multiple sclerosis (MS) is a tissue-specific autoimmune disease, characterized by immune
inflammation in the central nervous system (CNS) and chronic processes of demyelization.
In MS, the primary targets of immune response are myelin antigens, with the myelin basic
protein (MBP) usually described as the main target. Degradation of myelin impairs conduc‐
tive function of neurons and causes specific symptoms of the disease. The disease develops
in genetically predisposed individuals as a result of cross-reactivity of the immune system
to exogenous pathogenetic agents. According to PIFAS conception, the following stages can
be described in pathogenesis of MS:
1. Genetic predisposition.
2. Induction of immune response to antigens of myelin in genetically predisposed individ‐
uals, mediated by infectious processes in the CNS or by other factors.
3. Latent autoimmune inflammation in the CNS.
4. Latent impairment of neurological functions.
5. Manifestation of the disease in the form of clinically independent syndrome (CIS) or
primary progressive multiple sclerosis.
6.2. Genetic factors in pathogenesis of multiple sclerosis
For developing genetic markers of increased susceptibility to MS, three groups of genes are
usually studied: HLA genes, cytokine genes (IRF8, TNFa, CD6) and genes taking part in me‐
tabolism of myelin (MBP, CTLA1). (Dujmovic, 2011). Among genetic risk factors for MS, hu‐
man leukocyte antigen (HLA)-class II alleles, specifically the HLA DR and DQ loci, are the
best studied. It is currently thought that susceptibility to MS is defined not by individual al‐
leles, but rather by their interaction (conception of epistasis – interaction between certain al‐
leles of HLA). Lincoln and colleagues reported epistasis among 3 HLA-class II alleles (DRB1,
DQA1, and DQB1) in 2 independent Canadian cohorts. For example, HLADQ1*0102 in‐
creased MS risk when combined with HLADRB1*1501, thereby implicating the HLA-DQ
molecule in susceptibility to MS. Some alleles of HLA seem to reduce the risk of MS, an ex‐
ample being HLA-DRB1*01 (Fernandez-Morera et al., 2008, Isobe et al., 2010). In De Luca’s
study, HLA-DRB1*01 has been shown to be notably underrepresented in patients with ma‐
lignant cases of MS in comparison to those with benign cases (DeLuca et al., 2007), implicat‐
ing its role in determining the severity of the disease.
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Prognostically, some HLA alleles correlate with higher incidence of neutralizing Abs to IFN
b (HLA-DRB1*0408) (Caminero et al., 2011).
TNFRSF1A (TNFa) gene mutations also play a role in genetic predisposition to MS. A corre‐
lation has been found between MS and another autoimmune disease - TNF receptor-associ‐
ated periodic syndrome. The latter is firmly associated with TNFRSF1A mutations (IMSGC,
2011). Also, a link has been shown between MS and variants of several other cytokines, most
notably IR8 and CD6 (Yoon et al., 1989).
6.3. Clinical classification of multiple sclerosis. Natural history of multiple sclerosis
The first manifestation of MS is termed as clinical isolated syndrome – CIS. Diagnosis of MS
can be maintained after two distinct exacerbations of the disease, diagnosed clinically or in‐
strumentally – by MRI. Extensive data shows that about 80% of patients with CIS that have
changes in their MRI develop MS in 20 years. However, disease modifying treatment can in
certain cases prolong latent stages of the disease. Research of biomarkers determining risk of
progression to MS in the groups of risk is, therefore, of much importance. One of such mark‐
ers is Protein 14-3-3, which is thought to act as a chaperone in neurons and oligodendro‐
cytes. Protein 14-3-3 is a sensitive marker of damage to neural tissue, and it gas been shown
to be an independent factor in predicting conversion of CIS to MS.
An important moment in pathogenesis of MS is loss of protective function of the blood-brain
barrier (BBB). Normally, low permeability of BBB makes the CNS immunologically privi‐
leged, preventing immune response to its antigens. However, in MS this protective function
of the BBB is lost as a result of primary inflammatory response to infection or other factors
leading to damage to neurons and glial cells. Immunoregulatory defects including reduced
levels of regulatory T cells (Tr1, Th2, Th3) in MS patients allow myelin-reactive Th1-cells to
extravasate, cross the blood brain barrier (BBB) and enter the CNS. This barrier is not nor‐
mally accessible to T-cells, unless it is affected by a virus, which reduces the strength of the
junctions forming the barrier. Within the CNS, myelin-reactive Th1-cells interact with micro‐
glia (localized APCs) presented antigens and secret inflammatory cytokines (IL-2, IF gam‐
ma, TNFalpha) which initiate inflammatory cascades. Mononuclear phagocytes, T-cells and
microglia containing the RANTES (CCL5) (regulated on activation, normal T-cell expressed
and secreted) receptor CCR5 and T-cells containing the interferon-gamma-inducible protein
of 10 kDa (IP-10) (CXCL10); monokine induced by interferon-gamma (Mig) (CXCL9) recep‐
tor CXCR3 are targeted to the inflammation, demyelination sites by the RANTES and
IP-10/Mig chemokines, respectively.
An important mechanism mediating lymphoid cells migration in inflammatory conditions
increased expression of integrins,  such as VLA-4. Interacting with ICAM receptor of en‐
dothelial cells, VLA-4 plays an important role in the process of lymphocytes passing the
BBB.  That  makes  VLA-4  one  of  potential  targets  for  MS  therapy.  Immunomodulatory
therapy with interferon-beta also affects  BBB permeability,  reducing migration of  CD8+-
lymphocytes.
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Increased permeability of BBB allows antigen-specific lymphocytes and antibodies to reach
the CNS. However, clinically the disease may remain silent for some time: as it is common
with autoimmune diseases, MS is characterized with extended latent stage (third stage ac‐
cording to the conception of PIFAS). The silent autoimmune process can be identified by
presence of specific markers of the disease.
Clinically MS is categorized as either primary progressive MS (PPMS) (15% of cases at on‐
set) or relapsing-remitting MS (RRMS). The latter can evolve into secondary progressive MS
(SPMS), which takes place in about 65% of patients who presented with RRMS. Morphologi‐
cally progressive forms of the disease are characterized by diffuse inflammatory changes in
the CNS, while in RRRS inflammatory changes are local (Leech et al., 2007). Even healthy-
looking white matter of patients with progressive forms of MS shows increased permeabili‐
ty of the BBB, and this may be an evidence of diffuse inflammatory process in those forms of
the disease (DeStefano et al., 2001). Research of factors affecting clinical course of the disease
is of much importance. Disease evolution to secondary progressive variant may be mediated
by changes of the immune response, as well as by changes in target tissues. One of the
mechanisms involved in disease progression is transportation of the antigens to cervical
lymph nodes, with activation of new antigen-specific T-cells and expansion of antigen reper‐
toire. This doesn’t explain, however, why evolution to secondary-progressive variant is seen
only in certain subjects. The key role in this process is given to a previously discussed factor
- epitope spreading, taking place as a result of changes in conformation of myelin leading to
opening of previously inaccessible epitopes. Those epitopes may show higher affinity ro an‐
tigen-binding sequences of autoantibodies and autoreactive TCRs. Epitope spreading is ac‐
companied by changes in biomarker profiles, with occurrence of new antibody types. This
may be seen before clinical signs of secondary progressive MS. Another factor that might
play a role in MS transformation to secondary progressive type is degree of excitability of
neurons (Kutzelnigg et al., 2005). There is data that the CSF of patients with RRMS inhibits
activity of Na+-canals of neurons, which allows to presume it might show an in vivo effect
of reducing excitability of neurons. This might reduce the degree of neuronal damage and
serve as a “protective” factor preventing the development of SPMS.
An independent hypothesis of MS progression explains the development of SPMS as a natu‐
rally determined result of continuous disease progression (DeStefano et al., 2001). After
damage to CNS reaches a certain threshold, a break of compensation occurs after which fur‐
ther disease progression results in equivalent progression of functional disability. Before this
point, the clinical symptoms don,t fully reflect the severity of autoimmune process. This hy‐
pothesis explains low efficiency of disease-modifying treatment at the stage of SPMS. In the
light of such point of view, RRMS should be viewed as a state of partial compensation pre‐
ceding manifestation of the disease in the form of SPMS.
6.4. Pathology of multiple sclerosis. Role of infection in pathogenesis of multiple
sclerosis
The characteristic morphological feature of relapsing-remitting MS are MS lesions dissemi‐
nated in location and age. Typically, the plaques are located in the white matter of the CNS.
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The most frequent locations of the plaques are periventricular white matter, optic nerve and
the spinal cord. Another demyelization process can also usually be detected, affecting indi‐
vidual nerve fibers in the spinal cord. Even areas that are not affected by demyelization
process show abnormalities that some researchers believe may contribute to the pathogene‐
sis of progressive forms of the disease. MS plaques can be detected by functional diagnos‐
tics, and their localization correlates with clinical findings. Acute MS plaques show signs of
immune inflammation and degradation of myelin. The mechanisms active in MS plaques
are not completely understood. It is clear that damage to myelin, glial and neural cells is
mediated by classic immune effector mechanisms: cell-mediated cytotoxity and antibody
production. Cerebrospinal fluid and MS lesions of the patients show high levels of cytotoxyc
CD8+ cells specific to MBP, and neural and glial cells have been shown to increase produc‐
tion of MHC I molecules in conditions of immune inflammation, becoming targets for CD8+
cytotoxyc activity. How those mechanisms act together is, as of yet, unclear. Recent results
of have shed some light on this problem. They have described four morphological types of
inflammation in MS plaques (Luchinetti et al., 2000). Three of these mechanisms are typical
for RRMS, and the fourth type is characteristic for PPRS.
1. Demyelination associated with T-cell and macrophages-mediated inflammation.
2. Demyelination associated with T-cell and macrophages-mediated inflammation with
extensive antibody deposition in tissues and in glial cells. This pattern seems to be the
most common, and is associated with morphological signs of remyelination.
3. Demyelination associated with an infiltrate of T-lymphocytes and activation of macro‐
phages and microglia.
4. Demyelination associated with infiltration with T-cells. This pattern is found in PPRS
and is characteristic for this type of the disease.
This shows heterogenic nature of effector mechanisms active in MS. Authors of the study
hypothesize that different pathological patterns can represent different pathogenetic path‐
ways  of  the  disease  which  may  be  associated  with  different  prognosis  and  respond to
treatment.
In chronic plaques, the inflammatory process becomes inactive. Activated inflammatory
cells leave central areas of the plaque, while in the periphery, they retain their activity for
some time. During relapses of the disease, reactivation of some chronic plaques can follow.
This is accompanied by an increase in permeability of the BBB and by migration of macro‐
phages and antigen-specific T-cells.
The inflammatory process in MS plaques is accompanied by axonal degeneration. Acute
axonal degeneration can be morphologically detected by presence of axonal “ovoids”. Later
on, ovoids disappear, and morphological picture starts pointing at Wallerian degeneration.
Axonal damage in MS is thought to be irreversible, and to be responsible for chronic disabil‐
ity in MS patients. It has been shown that markers of neurodegeneration correlate well with
state of functional disability.
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As with IDDM, it is yet unclear (Anderson et al., 2009) whether the disease is initiated by
cross-reactivity of the immune system to MBP, or the primary event is morphological dam‐
age to the cells caused by infection or other factors. The immune initiation conception is the
more widely accepted one. It is supported by events of experimental transfer of MS to labo‐
ratory animals by one of the following ways: a) immunizing the animals with antigens of
myelin b) transplantating antigen-specific CD4+ cells. The latter experiments have become
the basis for viewing CD4+ cells as a key factor in disease initiation (as opposed to IDDM,
where CD8+ lymphocytes seem to be the key mediator of pathogenetic events, although
they are supported by CD4+ Th1-cells). In accordance with these views, blood of patients
with MS contains increased numbers of CD4++ cells specific to MBP.
The neural initiated conception views alteration of glial cells caused by chronic infection as
the initiating mechanism of the disease. While the speculation of the infectious factor being
the main etiological agent would seem too awkward, there is enough evidence to consider
some viruses persisting in the CNS as a factor initiating immune response. Cells of microglia
have been shown to raise expression of MHC molecules and inflammatory cytokines in con‐
ditions of tissue injury and viral infection. They are able to serve as APCs, playing an impor‐
tant role in primary recruitment of lymphocytes specific to antigens of myelin.
That  is  quite  logical,  seeing  as  antigen  mimicry  is  believed  to  play  quite  an  important
role in the pathogenesis of MS. MS is believed to initiate in genetically susceptible hosts,
when  common  microbes  that  contain  protein  sequences  cross-reactive  with  self-myelin
antigens activate antigen presenting cells (APC) in the blood. The most studied as a MS
risk  factor  is  Epstein-Barr  virus  infection.  In  Ascherio  et  al  study,  all  100%  of  patients
with MS were infected by EBV (Rudick, 2001). Frequency of MS in patients that had in‐
fectious  mononucleosis  is  higher  than  in  general  population.  It  has  been  shown  that
BCRs of  B-lymphocytes active towards MBP show homology with antibodies specific  to
EBV  latent  membrane  protein  1  (LMP1)  (Gabibov  et  al.,  2011).  However,  evidence  for
correlation between DNA load and frequency of  MS remain conflicting,  as  well  as  that
for similarity of geographic patterns of EBV infection and MS. In contrary, antiEBV anti‐
bodies seem to be a perfect risk marker, as their level in serum strongly correlates to fre‐
quency of MS (Andreoletti et al., 1998). This means that latent EBV infection seems to be
the  most  significant  risk  factor.  The  key  role  is  thought  to  belong  to  patterns  of  EBV
genes expression in latent state. Changes in methylation of the viral DNA might result in
increase in production of certain proteins involved in autoimmune response (Niller et al.,
2011). Other viruses that show high expression in tissues of MS patients are HHV-6 and
HERV.  Increase  of  expression  of  those  agents  might  contribute  to  disease  pathogenesis
by augmenting the inflammatory response against oligodendrocytes.
Another agent thought to be involved in MS pathogenesis is Acinetobacter. There is statisti‐
cally significant increase of anti-Acinetobacter antibodies in the serum of patients with MS.
There is also correlation between distribution of Acinetobacter sinusitis and MS. Also, DNA
sequences of Acinetobacter show homology with sequence of myelin.
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Current data suggest that infectious triggers are most likely ubiquitous, i.e., highly prevalent
in the general population, and that they require a permissive genetic trait which predisposes
for MS development.
As the disease progresses, the protective function of the BBB becomes chronically impaired.
Morphological investigation of tissues of patients with secondary progressive MS shows for‐
mation of lymphoid follicle-like structures in the meninges. Those follicles are hypothesized
to be the place of production of autoantibodies specific to various antigens of CNS. Those
include previously discussed anti-neurofilament antibodies.
Pathogenetic role of autoantibodies in MS remains unclear. While some researchers claim
that autoantibodies in MS just serve as a “witness” of pathological process mediated by oth‐
er mechanisms (such as cell-mediated cytotoxycity), there is data (Lincoln et al., 2010) show‐
ing that some antibody types may play a role in the disease progression through modifying
normal antigens of myelin and provoking specific immune response. This refers to catalytic
antibodies (abzymes) with proteolytic activity (antibody proteases). The typical mechanism
of catalysis for these antibodies is nucleophilic catalysis. Recently abzyme-dependent cata‐
lytic degradation of an autoantigen, MBP (myelin basic protein), was associated with the
course of the neurodegenerative disease MS and its rodent model, experimental autoim‐
mune encephalomyelitis (EAE). Autoantibody-mediated degradation of MBP was shown to
be site specific, with cleavage sites localized to the immunodominant epitopes of the pro‐
tein. These findings were supported by studies from others. Interestingly, this reaction was
inhibited in vitro by glatiramer acetate (Copaxone), an established treatment for MS. (Belo‐
gurov et al., 2008)
6.5. Prediction and prognosis: changes in the proteome characteristic for multiple
sclerosis
Main diagnostic criteria for MS are based on dissemination of clinical, instrumental, labora‐
tory findings. The three clinical stages of MS are preclinical phase, phase of immune inflam‐
mation and degenerative stage. In the preclinical phase there are no morphological changes,
but biomarkers of immune inflammation might already be found, although at low titers. At
this stage, abs to the “mimic” epitopes of microbial pathogens are found, supporting the
view that the disease is triggered by reaction of the immune system to such epitopes. The
process becomes self-supporting after immune respond shifts towards determinants of the
CNS. Preclinical diagnostics of MS aims at discovering autoantibodies before morphological
and/or clinical manifestation of the disease.
Markers of the autoimmune process in MS can be divided into two main categories: markers
of immune inflammation and markers of neurodegenerative processes. Biological fluids
used for sampling include blood serum and the cerebrospinal fluid (CSF). Advantages of us‐
ing blood serum include higher availability of the material, lower risk of the procedure and
economical advanteges. However, proteome of blood serum is less selective to pathology of
the central nervous system than that of the CSF. Certain markers are difficult to detect, and
there are technical problems associated with high-abundance proteins of the blood serum.
These have to be removed from the sample in order to reach diagnostically applicable levels
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of sensitivity and specifity. CSF is much more convenient in terms of sample preparation,
sensitivity and specifity. However, obvious reasons prevent widely using it for screening,
expecially in healthy individuals.
Non-specific markers of immune inflammation include oligoclonal IgG bands, light Ig
chains, chromogranin A, clusrerin, CC3.
Markers specific to autoimmune processes taking place in MS are autoantibodies to myelin
basic protein (anti-MBP) and to myelin oligodendrocyte protein (anti-MOG). Antibodies
found in MS patients include anti-myelin basic protein antibodies, antiganglioside antibod‐
ies, anti-myelin oligodendrocyte glycoprotein antibodies (Yoon et al., 1990). Anti-MBP anti‐
bodies are the most common markers used for preclinical diagnostics. To raise the specifity
of the method, selective reactivity of autoantibodies to certain MBP fragments can be meas‐
ured. It should be noted that anti-MBP antibodies are also found in some healthy people.
Antiganglioside (AGM)-antibodies are found in patients with various neurological disor‐
ders and are not specific for MS. However, they can be used for prognostic purposes. There
ere several subtypes of anti-AGM antibodies. Presence of several common AGM-antibodies
as opposed to typical AGM-1 antibodies reflects high degree of disease progression. Clini‐
cally this correlates with secondary-progressive form of MS and bad prognosis.
Myelin oligodendrocyte protein is a superficial component of myelin. In animal models, this
protein has been shown to be quite vulnerable to both cell and humoral immune response. It
is thought to be one of the primary targets in initiation of MS. Antibodies to this protein
might offer a promising perspective for preclinical diagnostics of MS. MOG is the most in‐
teresting candidate B-cell autoantigen in MS. Because of its location it is an ideal target for
antibody-mediated demyelination. Anti-MOG antibodies are indeed able to cause myelin
destruction in EAE models, while other antibodies against major myelin proteins such as
MBP or PLP, which are both not located on the myelin surface, do not cause myelin destruc‐
tion on their own. Anti-MOG Abs mediate a characteristic vesicular transformation of com‐
pact myelin in acutely demyelinated lesions that also has been documented in human MS
lesions strongly suggesting a role of anti-MOGAbs in MS. The B-cell response to MOG is en‐
hanced in MS also supporting the pathogenic importance of anti-MOG Abs.
Antiganglioside antibodies (anti-GM) are more of prognostic value, as there is a correlation
between anti-GM antibody type and clinical type of the disease (primary progressive, back-
and-remitting, secondary progressive).
Prognostic use of antibodies is based on the fact that correlation can be made between types
of main determinants and antibodies and prognosis/ clinical stage of the disease. In the
course of the disease, autoantibodies cause changes in myelin structure, which leads to for‐
mation of new, more immunogenic epitopes, and changes in autoantibodies specter. Clini‐
cally this is accompanied by transformation of MS into secondary-progressive form. While
the disease progresses, immune inflammation becomes less specific, with initiation of im‐
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mune response to various determinants of the CNS as opposed to primary response which
affects just the components of myelin.
It is necessary to note, however, that markers of immune inflammation do not show exact
correlation with degree of axonal damage, although changes in antibody profiles can be use‐
ful in predicting evolution to secondary progressive clinical type. That is why markers of
neurodegeneration are just as important.
Markers of neurodegeneration are components of structures altered during the clinical at‐
tack of MS. The body fluid that reflects their level most accurately is the CNF. However, it is
often inconvenient to use CSF, making it necessary to use blood as the more accessible mate‐
rial, although its proteome doesn,t reflect proteome of the CNS as accurate as CSF does.
One of  such markers is  NF-L – the light  chain of  neurofilaments constituting cytoskele‐
ton of axons. NF-l is raised in a number of neurodegenerative diseases, reflecting axonal
damage.  There  is  also  correlation between NF-L levels  and exacerbation of  the  disease,
and an increase in NF-L levels has been detected in patients with CIS prior to manifesta‐
tion of  MS. (3 years).  In patients with MS it  is  also not uncommon to detect  antibodies
against  neurofilaments  –  anti-nerofilament  antibodies.The  best  studied  marker  is  the
main target of autoimmune reactions in MS – myelin basic protein (MBP). MBP is is one
of  the most  abundant  proteins  of  myelin,  and is  present  in  both central  and peripheral
nervous system. High levels of MBP have been shown to correlate with upcoming relap‐
ses of MS, as well as with the disease attaining the progressive clinical type. In combina‐
tion with anti-MBP and anti-MOG antibodies, detection of fragments of MBP can be used
for predicting relapses in the course of the disease (Huang et al., 2011). Another prognos‐
tic marker is acidic calcium-binding protein – a component of axons damaged during the
course of the disease.  Tau-protein – a cytoskeleton protein involved in formation of mi‐
crotubules,  is  another  marker  of  neurodegeneration.  Changes  in  phosphorilation  of  the
protein lead to impairment of axonal transport, and to formation of insoluble neurotoxic
aggregates.  In patients with MS, levels of abnormally phosphorilated tau-protein have a
tendency to rise with time (Lincoln et al., 2009).
7. Conclusion
The pathogenesis of autoimmune diseases is a complex process, with both genetic and envi‐
ronmental factors playing equally important role. In genetically predisposed organisms, the
key event promoting the start of autoimmune response is often infection, usually with a vi‐
ral pathogen. There is a variety of specific patterns by which infections can contribute to au‐
toimmunity. Those patterns were analyzed in the light of fundamental conceptions of
autoimmunity. Also, models of infectious pathogens inducing autoimmune processes were
discussed on the base of two autoimmune conditions: IDDM and MS, both of which seem to
fit the introduced model.
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